Orgenesis Inc Stock Price, News & Analysis

Welcome to our dedicated page for Orgenesis news (Ticker: ORGS), a resource for investors and traders seeking the latest updates and insights on Orgenesis stock.

Orgenesis Inc. (ORGS) generates frequent news as a global biotech company focused on cell and gene therapies (CGTs) and a decentralized approach to cell processing. News about the company often highlights progress on its therapeutic pipeline, developments in its decentralized platforms, and key financing and strategic agreements that shape its business trajectory.

Recent announcements include positive real-world study results for ORG-101, a CD19 CAR-T therapy for patients with CD19+ Acute Lymphoblastic Leukemia, along with plans to initiate Phase 1/2 multicenter clinical studies at hospitals in Greece supported by an Enterprise Greece grant. Orgenesis has also reported the acquisition of GMP-validated platforms for producing CAR-T, tumor-infiltrating lymphocytes, lentivirus vectors, oncolytic virus cell carriers, and therapeutic exosomes, which it integrates into its decentralized production model.

News coverage also follows Orgenesis’ corporate and strategic moves. The company has announced a joint venture with Harley Street Healthcare Group to develop wellness and longevity services and products, including immune cell banking and regenerative therapies. It has reported a strategic collaboration to manufacture, co-market, distribute, and service its Orgenesis Mobile Processing Units and Labs (OMPULs), as well as partnerships and grants that support decentralized production of Advanced Therapy Medicinal Products and therapeutic exosomes.

Investors and observers can also track financing developments, such as equity investments, an equity line of credit with Williamsburg Venture Holdings, and a Convertible Loan Agreement involving Theracell, an indirect subsidiary. Trading venue updates, including a reverse stock split and the transition from Nasdaq to the OTCQX Best Market under the ORGS symbol, are additional recurring topics. This news page aggregates these earnings updates, clinical milestones, partnership announcements, financing transactions, and regulatory disclosures in one place for ongoing monitoring.